These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18237459)

  • 1. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
    Müller T; Przuntek H; Rieks M; Mackowiak A
    Neurol Res; 2008 May; 30(4):417-9. PubMed ID: 18237459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
    Naoi M; Maruyama W; Inaba-Hasegawa K; Akao Y
    Int Rev Neurobiol; 2011; 100():85-106. PubMed ID: 21971004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
    Naoi M; Maruyama W
    Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
    Naoi M; Maruyama W; Shamoto-Nagai M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2018 Nov; 125(11):1635-1650. PubMed ID: 29279995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
    McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
    Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
    Tatton WG; Wadia JS; Ju WY; Chalmers-Redman RM; Tatton NA
    J Neural Transm Suppl; 1996; 48():45-59. PubMed ID: 8988461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils.
    Erdö F; Baranyi A; Takács J; Arányi P
    Neuroreport; 2000 Aug; 11(11):2597-600. PubMed ID: 10943729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.